Navigation Links
TorreyPines Therapeutics Reports Third Quarter 2007 Results
Date:11/14/2007

rch and development 8,161 4,470 20,390 17,640

General and administrative 1,351 680 4,209 1,986

Total operating expenses 9,512 5,150 24,599 19,626

Loss from operations (7,049) (2,687) (17,211) (12,238)

Other income (expense)

Interest income 504 259 1,699 732

Interest expense (193) (279) (647) (735)

Other income (expense), net (36) - 946 2

Total other income (expense) 275 (20) 1,998 (1)

Net loss (6,774) (2,707) (15,213) (12,239)

Dividends and accretion

to redemption value of

redeemable convertible

preferred stock - (1,237) - (3,534)

Net loss attributable

to common stockholders $(6,774) $(3,944) $(15,213) $(15,773)

Basic and diluted net

loss per share

attributable to common

stockholders* $(0.43) $(7.18) $(0.97) $(29.19)

Weighted average shares

used in the computation

of basic and diluted net

loss per share

attributable to

common stockholders *15,733,970 549,481 15,711,212 540,395

* Basic and diluted net loss per share attributable to common

stockholders and weighted average shares outstanding were impacted by

the conversion of preferred stock and issuance of common stock in

connection with the Axonyx merger.


'/>"/>
SOURCE TorreyPines Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
2. TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference
3. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
4. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
5. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
8. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
9. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
10. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
11. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... , October 30, 2014 Investor-Edge ... Inc. (NYSE MKT: ONVO), Medivation Inc. (NASDAQ: ... Synthetic Biologics Inc. (NYSE MKT: SYN), and Ironwood Pharmaceuticals ... can be accessed at: http://investor-edge.com/register . ... at 4,549.23, down 0.33%, the Dow Jones Industrial Average ...
(Date:10/30/2014)... Chicago, Illinois (PRWEB) October 30, 2014 ... Regenerative and Cellular Medicine Showcase in Chicago, leading ... and Orthopedic Surgeon, Dr. Wade McKenna presented talks ... Effectiveness and Orthopedic Surgical Applications For Stem Cells. ... of amniotic membrane and the properties of AlphaGEMS ...
(Date:10/30/2014)... Spartan Bioscience announced today that Health Canada has ... detects CYP2C19 genetic mutations in less than 60 minutes ... CYP2C19 System is the first near-patient DNA test for ... to the system’s ease of use, Health Canada has ... such as doctors, nurses, pharmacists, and laboratory technicians, in ...
(Date:10/30/2014)... , Oct. 30, 2014 Isis Pharmaceuticals, Inc. ... today announced that management will present a company overview at ... 8:30 a.m. ET in Boston, MA. ... available on the "Investors & Media" section of the Company,s ... the Isis website within 48 hours and will be archived ...
Breaking Biology Technology:Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 2Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 3Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 4Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 5Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 2Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 3Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 4Health Canada approves first near-patient DNA test for personalized medicine 2Health Canada approves first near-patient DNA test for personalized medicine 3Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2
... Society, an,international association focused on endocrinological research and,practice, today ... ENDO 08, the annual conference of the Society, which ... over 14,000 members from 80,countries, many of whom attend ... research and clinical care., The purpose of today,s ...
... industry, academia, government and health providers draws dozens of ... ... June 16 The unique connectivity, talent and,collaboration that has ... in recent years will be on show at BIO 2008 ...
... today announced,the appointment of Jim Meade, Ph.D., ... addition to contributing to the strategic direction ... for managing the development of,Lentigen,s partnerships, stakeholder ... and other key aspects of,corporate development., ...
Cached Biology Technology:'Breakthroughs Ahead,' Endocrine Society Tells Security Analysts 2Scotland Showcased at BIO as Dynamic, Global Life Sciences Hub 2Scotland Showcased at BIO as Dynamic, Global Life Sciences Hub 3Lentigen Appoints Jim Meade as Vice President of Corporate Development 2
(Date:10/30/2014)... October 30, 2014 – Bacteria in the gastrointestinal ... for digestion. Yet, these same bacteria can induce ... they penetrate the gut and enter the bloodstream. ... to protect the body, chronic or systemic inflammation ... research has established the involvement of inflammatory processes ...
(Date:10/30/2014)... | Heidelberg, 30 October 2014 Biological membranes are ... understanding of adsorption of solution ions onto lipid ... Now, a new study provides a quantitative description ... solution ions. Joanna Kotyńska and Zbigniew Figaszewski from ... of a study describing these findings, just published ...
(Date:10/29/2014)... released by unconventional oil and gas production are well ... in the open access journal Environmental Health . ... found. The study is the first to be based ... sites and could be used to supplement official air-quality ... reserves that do not readily flow to the surface. ...
Breaking Biology News(10 mins):Breakdown in gut barriers to bacteria may promote inflammation and craving in alcoholics 2Ion adsorption matter in biology 2Air quality and unconventional oil and gas sites 2Air quality and unconventional oil and gas sites 3
... stage is set for the local fauna! ,Computer scientists ... birdsong archives of Berlin,s Humboldt University, have developed a kind ... with entertainment, but a lot to do with the protection ... reliably recognise the characteristic birdsong of different species of birds, ...
... drop to dangerously low levels in diseases such as ... critical cells, doctors filter platelets from donated blood, but ... infections and cause other side effects in patients who ... scientists have been trying to generate platelets from embryonic ...
... on opposite sides of a canyon have evolved to cope ... or cell membranes. Scientists have found that bacteria change these ... looking at the appearance of the bacteria as well as ... August issue of Microbiology , will start a new ...
Cached Biology News:Birdsong not just for the birds 2Bacteria reveal secret of adaptation at Evolution Canyon 2
... Agencourt offers pre-validated ... over 1500 amplicons within ... serine/threonin kinases, and more ... These assays were ...
Glycerol-based mounting medium for immunofluorescence microscopy. Formulated to retard photobleaching of fluorochromes such as fluorescein and rhodamine. Product can also be used as a diluent for fl...
... Mouse anti-Yersinia pestis F1 antigen, ... Applications: ELISA: Use at ... at an assay dependent dilution. WB: ... Predicted molecular weight: 18 kDa. Not ...
Anti-Phospho-JKK/SEK1/MKK4 pAb Description: 100 g rabbit polyclonal antibody. Reacts with human/mouse/rat. Tested in WB. Research Focus: signal transduction Storage: -20C Shipping Tem...
Biology Products: